Results 61 to 70 of about 54,977 (304)

Clinical characteristics of second primary pancreatic cancer.

open access: yesPLoS ONE, 2017
PurposeSeveral studies reported the increased risk of second primary pancreatic ductal adenocarcinoma (2nd PDAC) in cancer survivors. However, data on the characteristics of 2nd PDAC are insufficient.MethodsThis retrospective cohort study included 1759 ...
Jung Hyun Jo   +9 more
doaj   +1 more source

Plasma Gelation as an Overlooked Determinant of Transfection Efficiency in Protein Corona‐Coated Lipid Nanoparticles: Implications for In Vitro–In Vivo Translation

open access: yesAdvanced Healthcare Materials, EarlyView.
Upon contact with plasma, lipid nanoparticles (LNPs) rapidly acquire a protein corona (PC) that redefines their biological identity. In calcium‐containing environments, these coronated particles trigger the formation of a gel‐like plasma network, profoundly altering their transport properties and reducing their effective availability.
Serena Renzi   +14 more
wiley   +1 more source

Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma

open access: yesJournal of Translational Medicine, 2023
Background Lysosomes are closely linked to autophagic activity, which plays a vital role in pancreatic ductal adenocarcinoma (PDAC) biology. The survival of PDAC patients is still poor, and the identification of novel genetic factors for prognosis and ...
Youngil Koh   +20 more
doaj   +1 more source

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan

open access: yesGut and Liver, 2023
Resection is the only curative treatment for pancreatic ductal adenocarcinoma (PDAC). Although the outcome of technically resectable PDAC has improved with advances in surgery and adjuvant therapy, the 5-year survival rate remains low at 20% to 40%. More
Shigenori Ei   +5 more
doaj   +1 more source

CDX2 expression in PDAC.

open access: yes, 2014
CDX2 is largely negative (A) in PDAC, but can be weakly (B) and moderately positive (C and D) (×20).
Amad Awadallah (516772)   +4 more
core   +1 more source

In‐House Manufacturing of 3D ECM Culture Chips via Vacuum Thermoforming for Enhanced Imaging Applications

open access: yesAdvanced Materials Technologies, EarlyView.
Desktop vacuum thermoforming enables rapid, low‐cost fabrication of 96‐channel polystyrene culture chips with very thin imaging interfaces. The resulting platform supports cell lines, primary cells, and patient‐derived organoids, and enables high‐resolution confocal microscopy and single‐cell visualization, providing an accessible approach for advanced
Aleksandra Fomina   +5 more
wiley   +1 more source

Prevalence of diabetes mellitus and altered fasting blood glucose at the time of pancreatic cancer diagnosis, in a group of patients assisted in a gastroenterological referral center in Argentina

open access: yesRevista de la Sociedad Argentina de Diabetes, 2021
Introduction: diabetes mellitus (DM) is considered to be a risk factor for the development of pancreatic ductal adenocarcinoma (PDAC). Objectives: describe the prevalence of DM and of impaired fasting glucose (IFG) at the diagnosis of PDAC, among ...
Ana Florencia Costa   +6 more
doaj   +1 more source

SMAD4 Y353C promotes the progression of PDAC [PDF]

open access: yesBMC Cancer, 2019
Abstract Background SMAD4 is frequently inactivated and associated with a poor prognosis in pancreatic ductal adenocarcinoma (PDAC). Abnormal SMAD4 expression also plays an important role in the malignant progression of PDAC.
Zusen Wang   +9 more
openaire   +3 more sources

MMP9 and S100A9 Expression in Peripheral Blood Mononuclear Cells (PBMC) Are Correlated with Pancreatic Adenocarcinoma (PDAC) and with PDAC-Associated Diabetes Mellitus. [PDF]

open access: yes, 2013
Context Tumor-stroma-endocrine interactions favour pancreatic adenocarcinoma (PDAC) growth/ progression and PDAC-associated diabetes mellitus (DM). S100A8/A9 and the matrix methallo­proteinases (MMPs) 8 and 9 are overexpressed in PDAC stroma.
MOZ, STEFANIA   +19 more
core   +1 more source

AI‐Powered Framework for Evaluating Drug Efficacy for Three‐Dimensional In Vitro Cancer Models in Robot‐Assisted Production

open access: yesAdvanced Robotics Research, EarlyView.
An AI‐powered, robot‐assisted framework automatically produces, images, and analyzes 3D tumor spheroids to evaluate drug efficacy. Integrated modules handle spheroid formation, live/dead staining, brightfield imaging, and automated image analysis, including spheroid segmentation, viability and metrics to assess the drug treatment efficacy. The workflow
Dalia Mahdy   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy